Owl Therapeutics to present novel approach to Unlocking the Traumatic Brain Injury Market

SAN ANTONIO, Sept. 9, 2024 /PRNewswire/ — Owl Therapeutics (“Owl”), a clinical-stage biopharmaceutical company specializing in artificial intelligence (AI) and diagnostic-powered neurotherapeutics for Traumatic Brain Injury (TBI) and related indications, will present its novel clinical…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.